• Information accompanying the revision of the consumption tax rate

  • Ajinomoto Bio-Pharma Services Acquires Remaining Interest in Granules OmniChem Joint Venture in India

  • Information on Service Brand Name Change

  • GeneDesign Joins Ajinomoto Bio-Pharma Services and Opens Oligonucleotide API Development Center

  • Jean-Baptiste Agnus Joins Ajinomoto Bio-Pharma Services’ Global Leadership Team as Vice President of Sales and Marketing

  • Ajinomoto Bio-Pharma Services Announces Capital Expansion to Fuel Growth

  • Ajinomoto and XL-protein forge Strategic Alliance to develop PASylated therapeutics applying the Corynex® platform

  • Ajinomoto Bio-Pharma Services Introduces AJICAP Bioconjugation Technology for ADC Manufacturing

  • Precision NanoSystems Announces Manufacturing Collaboration Agreement with Ajinomoto Bio-Pharma Services for GMP Manufacturing of High Quality Nanomedicines

  • Ajinomoto Althea and OmniChem Combine to Form Ajinomoto Bio-Pharma Services, Reflecting a Collective Range of Services Offered to the Bio-Pharma Industry

  • Ajinomoto Althea, Inc. Announces Additions to Management Team as it transforms into a global CDMO

  • The Government of Flanders recently agreed to participate in Ajinomoto OmniChem’s investments into new and innovative technologies.